MERCK SHARP & DOHME CORP.

Patent Owner

Watch Compare Add to Portfolio

Stats

Details

Patent Activity in the Last 10 Years

Technologies

Intl Class Technology MATTERS Rank in Class
 
 
A61K PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES 1559 4
 
 
C07D HETEROCYCLIC COMPOUNDS 1226 1
 
 
C07K PEPTIDES 248 11
 
 
A01N PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF 177 11
 
 
C12N MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF 170 40
 
 
C07H SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 138 13
 
 
A61P THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 107 2
 
 
C07C ACYCLIC OR CARBOCYCLIC COMPOUNDS 103 50
 
 
C12P FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE 92 27
 
 
G01N INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 70 136
  • No Technologies to Display

Top Patents (by citation)

Recent Publications

Publication # Title Filing Date Pub Date Intl Class
2018/0071,247 COMBINATION OF A PD-1 ANTAGONIST AND ERIBULIN FOR TREATING CANCER Mar 03, 16 Mar 15, 18 [A61K, C07K]
2018/0071,412 PYRROLO[2,3-C]PYRIDINES AS IMAGING AGENTS FOR NEUROFIBRILARY TANGLES Oct 04, 17 Mar 15, 18 [C07D, A61K]
2018/0065,999 ANTIVIRAL BETA-AMINO ACID ESTER PHOSPHODIAMIDE COMPOUNDS Sep 25, 17 Mar 08, 18 [C07F, A61K]
2018/0066,055 ANTI-TIGIT ANTIBODIES Nov 20, 17 Mar 08, 18 [A61K, C07K]
2018/0055,867 METHODS FOR THE TREATMENT AND PROPHYLAXIS OF HIV AND AIDS Feb 10, 17 Mar 01, 18 [A61K]
2018/0051,028 PYRAZOLOPYRIMIDINE INHIBITORS OF IRAK4 ACTIVITY Mar 07, 16 Feb 22, 18 [C07D, A61K]
2018/0051,030 PYRROLOTRIAZINE INHIBITORS OF IRAK4 ACTIVITY Mar 07, 16 Feb 22, 18 [C07D, A61K]
2018/0044,395 PROCESS FOR PREPARING RECOMBINANT INSULIN USING MICROFILTRATION Mar 03, 16 Feb 15, 18 [C12P, C07K]
2018/0044,418 COMBINATION OF A PD-1 ANTAGONIST AND VORINOSTAT FOR TREATING CANCER Mar 15, 16 Feb 15, 18 [A61K, C07K]
2018/0029,981 Process for Making Beta 3 Agonists and Intermediates Sep 26, 17 Feb 01, 18 [C07D, C12P]

View all publication…

  • No Publications to Display

Recent Patents

Patent # Title Filing Date Issue Date Intl Class
9920038 Methyl oxazole orexin receptor antagonists Nov 30, 15 Mar 20, 18 [C07D, A61K]
9914727 Factor IXa inhibitors Dec 16, 13 Mar 13, 18 [C07D]
9914736 TrKA kinase inhibitors, compositions and methods thereof Mar 23, 15 Mar 13, 18 [C07D, A61K]
9907849 Combination of a PD-1 antagonist and a listeria-based vaccine for treating prostate cancer Jul 17, 15 Mar 06, 18 [A61K, G01N]
9909185 Diagnosis and prognosis of breast cancer patients Oct 19, 12 Mar 06, 18 [C12Q, G06F, G01N]
9896447 TrkA kinase inhibitors, compositions and methods thereof Sep 17, 14 Feb 20, 18 [C07D]
9889205 Glucose-responsive insulin conjugates Jun 24, 16 Feb 13, 18 [A61K, C07K]
9890128 Process for making substituted quinazoline compounds Dec 08, 14 Feb 13, 18 [C07D, B01J]
9890378 Surface anchored light chain bait antibody display system May 06, 13 Feb 13, 18 [C12N, C40B, G01N, C07K]
D810283 Medical injector pen Nov 10, 16 Feb 13, 18 [2402]

View all Patent…

  • No Patents to Display

Expired/Abandoned/Withdrawn Patents

Patent # Title Status Filing Date Issue/Pub Date Intl Class
2017/0247,336 SUBSTITUTED PYRIMIDINES AS INHIBITORS OF HIF PROLYL HYDROXYLASE Abandoned Oct 08, 15 Aug 31, 17 [C07D]
2017/0248,580 METHOD FOR SCREENING DRUG-SACCHARIDE CONJUGATES Abandoned May 15, 17 Aug 31, 17 [G01N]
2017/0240,513 SUBSTITUTED PYRIMIDINES AS INHIBITORS OF HIF PROLYL HYDROXYLASE Abandoned Oct 08, 15 Aug 24, 17 [C07D]
2017/0240,539 Preparation and Use of Cyclic Sulfonamide Derivatives as PAR-1 Receptor Antagonists Abandoned Oct 09, 15 Aug 24, 17 [C07D]
2017/0233,477 CELL LINE 3M Abandoned Apr 12, 17 Aug 17, 17 [C12P, C07K]
2017/0226,550 INHIBITORY RNA FOR ENHANCED PROTEIN PRODUCTION IN RECOMBINANT MAMMALIAN CELLS Abandoned Aug 04, 15 Aug 10, 17 [C12N, C12P]
2017/0216,295 CCR9 ANTAGONIST COMPOUNDS Abandoned Jul 27, 15 Aug 03, 17 [C07D, A61K]
2017/0198,042 ANTI-TIGIT ANTIBODIES Abandoned Mar 22, 17 Jul 13, 17 [A61K, C07K]
2017/0190,701 FUSED TRICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INTEGRASE INHIBITORS Abandoned Dec 22, 16 Jul 06, 17 [C07D, A61K]
2017/0166,586 PROCESS FOR MAKING TETRACYCLIC HETEROCYCLE COMPOUNDS Abandoned Jul 10, 15 Jun 15, 17 [C07F, C07D, C07C]
2017/0066,715 AMIDATION PROCESS Abandoned Nov 21, 16 Mar 09, 17 [C07C]
2017/0066,795 SOLID PRODRUG FORMS OF 2'-CHLORO-2'-METHYL URIDINE FOR HCV Abandoned Mar 05, 15 Mar 09, 17 [C07H, A61K]
2017/0008,906 INHIBITORS OF HEPATITIS C VIRUS REPLICATION Abandoned Sep 22, 16 Jan 12, 17 [C07D, A61K]
2016/0355,589 ANTI-TIGIT ANTIBODIES Abandoned Aug 17, 15 Dec 08, 16 [A61K, C07K]
2016/0356,794 ANTIBODIES THAT BIND TO HUMAN TAU AND ASSAY FOR QUANTIFYING HUMAN TAU USING THE ANTIBODIES Abandoned Feb 09, 15 Dec 08, 16 [A61K, G01N, C07K]
2016/0339,074 PHARMACEUTICAL COMPOSITION OF SELECTIVE HCV NS3/4A INHIBITORS Abandoned Feb 03, 15 Nov 24, 16 [A61K]
2016/0311,791 NOVEL TRICYCLIC CALCIUM SENSING RECEPTOR ANTOGONISTS FOR THE TREATMENT OF OSTEOPOSOSIS Abandoned Dec 17, 14 Oct 27, 16 [C07D, C07C]
2016/0279,140 CEFTOLOZANE ANTIBIOTIC COMPOSITIONS Abandoned Mar 31, 16 Sep 29, 16 [A61K]
2016/0257,668 Factor XIa Inhibitors Abandoned Oct 06, 14 Sep 08, 16 [C07D, C07C]
2016/0257,697 THIOPHENE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND METHODS OFUSE THEREOF FOR THE TREATMENT OF VIRAL DISEASES Abandoned Dec 31, 13 Sep 08, 16 [C07D, A61K]

View all Patent…

  • No Patents to Display

Top Inventors for This Owner

We are sorry but your current selection exceeds the maximum number of watches () for this membership level. Upgrade to our Level for up to watches!

Owner Watch
MERCK SHARP & DOHME CORP.
CANCEL
UPGRADE MEMBERSHIP CANCEL

We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to comparisons!

UPGRADE MEMBERSHIP CANCEL

We are sorry but your current selection exceeds the maximum number of portfolios () for this membership level. Upgrade to our Level for up to portfolios!

UPGRADE MEMBERSHIP CANCEL

We are sorry but your current selection exceeds the maximum number of patents allowed in portfolios () for this membership level. Upgrade to our Level for up to patents!

UPGRADE MEMBERSHIP CANCEL